A new eye-focused biotech is out of stealth, with plans to barrel toward PhII studies

Paul Schloesser

Associate Editor

A new biotech emerged from stealth and joined the Massachusetts biotech scene this morning, announcing its launch with a Series A for $10.5 million. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A new eye-focused biotech is out of stealth, with plans to barrel toward PhII studies

Paul Schloesser

Associate Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Revolution’s KRAS drugs appear competitive in several lung cancer settings

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

A new eye-fo­cused biotech is out of stealth, with plans to bar­rel to­ward PhII stud­ies

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A new eye-focused biotech is out of stealth, with plans to barrel toward PhII studies